Advanced Search:
Equity Index Forex Crypto Commodity

TGTX - TG Therapeutics

$16.48  -0.94 (-5.4%)

Updated: 17:08 May 19, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

TG Therapeutics's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

TG THERAPEUTICS - HISTORICAL DATA 6M

  • Last price

    $ 16.48

  • Daily change

    $ -0.94

  • Previous Close

    $ 17.42

  • Last Updated

    17:08 May 19, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-2.92 0.96 0.45 0.27 -0.33

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
2.92 2.99 2.57 3.07 3.61

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 0% 68.1% 64.36%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
16.48 -3% 16.99 11.56% 15.23 -0.2% 15.26

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.59 45.95 2.44 61.39

TG Therapeutics Technical Analysis News

TG Therapeutics

2 Gansevoort Street
9th Floor
New York, NY 10014
United States
212 554 4484
http://www.tgtherapeutics.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 301
Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.

Corporate Governance

TG Therapeutics, Inc.’s ISS Governance QualityScore as of June 30, 2021 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 4; Compensation: 10.

TG THERAPEUTICS'S HOLDERS RANK

List of holders with stock participation in TG Therapeutics.

Holder Rank Holder Shares Date Reported % Out Value